Stephen K. Burley


Stephen Kevin Burley is a British-born scientist, naturalized in both Canada and the United States. He is known as an expert in structural biology, proteomics, structure/fragment based drug discovery, and clinical medicine/oncology.
He joined Rutgers, The State University of New Jersey in 2013, where he is a University Professor and Henry Rutgers Chair. Burley directs the RCSB Protein Data Bank, the, and the .

Career

Burley has a Bachelor in physics from the University of Western Ontario and a D.Phil from Oxford University, England in Molecular Biophysics as a Rhodes scholar. Burley has an M.D. from Harvard Medical School.
He worked with Gregory A. Petsko and William N. Lipscomb at MIT and Harvard. He was faculty at Howard Hughes Medical Institute and Rockefeller University.
Burley co-founded Prospect Genomics, Inc, a computational genomics pharma. He was Chief Scientific Officer of SGX Pharmaceuticals after it acquired Prospect. SGX was in turn merged with Eli Lilly in 2008 where Burley was a Distinguished Lilly Research Scholar in Lilly Research Laboratories
In 2012 Burley joined Rutgers as Director of the Center for Integrative Proteomics Research and became director of the RCSB PDB in 2014, succeeding Prof. Helen Berman
He is a member of the Editorial Board for Oncogene.

Honors and awards